Consistent with tissue-based findings, Dagogo et al., evaluated concordance between plasma ctDNA (Guardant360) and tissue biopsy for ROS1 fusion detection in NSCLC, both at diagnosis and after progression on crizotinib. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.